NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Crossover can cause confoundment beyond what you imagine. Because Temodar interferes with t-cells, often causing premature exhaustion, the trx group in the trial used DCVax-l when the immune system was compromised, thus potentially making a less aggressive response. A less aggressive response, can potentially in turn result in a muted long term immunity, because the immune system thinks the cancer is not that big of a deal — in some cases.

Whereas, in rGBM, Temodar is stopped before DCVax-l is started. So when DCVax-l induced clonal expansion of t-cells occurs, those tumor killing t-cells can have an aggressive response, thus also creating better memory response and charging up the immune system, because no Temodar is there to stunt the immune response.

You also do not know what the OS differential is for the control versus experimental arm.